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Summary 
Introduction: All western healthcare systems are confronted with a rising 
number of new health technologies. These new technologies bring particular 
challenges, not only in terms of financial burdens but they also raise ques-
tions concerning managed introduction, reimbursement, organizational re-
quirements, changes in medical practice or social and ethical problems. De-
cisions have to be made not only concerning degree and time of adoption 
and/or reimbursement but also concerning treatment policies. To support 
these decision making processes with sound information about new health 
technologies, some countries have established “Horizon Scanning”, “Early 
Warning” or “Alert” Systems. Currently there are 13 government-funded or-
ganizations that undertake substantial activities in this field. Since 1999 they 
have been collaborating in the EuroScan network. This report presents an 
overview of methods, processes, similarities and differences between the many 
Horizon Scanning activities. 
Objective: Within EUnetHTA, it is the task of WP 7 (Strand B) to develop a 
European-wide newsletter on emerging technologies. This review aims at sup-
porting the newsletter development with transparent criteria for the selec-
tion of new technologies that will be reported on.  
Method: The report is based on a literature review, on unpublished informa-
tion gathered from the relevant agencies (Horizon Scanning Systems/HSS) 
and on personal e-mail contacts with staff members. It was reviewed by Carla 
Douw/CAST. 
Results: As a first step towards a broader understanding, EuroScan agreed on 
a common terminology, classification and understanding of their activities. 
Definitions refer to the object and components of HSS. The harmonization 
of the criteria to select and prioritize new technologies is another activity of 
international co-operations. 
Definitions of subject: HSS is concerned with new or emerging technologies, 
but also established technologies with new indications or technologies that 
are part of a group of developing technologies that may as a whole have an 
impact. A new technology is one that is in the phase of adoption, has only 
been available for clinical use for a short time and is generally in the launch 
or early post marketing stages. In contrast an emerging technology is defined 
as ‘not yet adopted to the health care system’. In the case of pharmaceuticals 
it will be in phase II or phase III clinical trials or pre-launch. Medical devices 
will be prior to marketing or within 6 months of marketing or marketed but 
<10 % diffused or localised to a few centres. The time horizon is 0-5 years 
before introduction.  
Function: The fundamental function of HSS is to support policy makers by 
providing them with timely information on new health technologies and pos-
sible consequences for the healthcare system. Their need to control the adop-
tion and diffusion of new technologies in health care by pushing or slowing 
down the speed of diffusion process is the objective of HSS.  
 
Horizon Scanning for 
early identification and 
assessment of important 
new health technologies 
objektive: supporting 
development of 
newsletter on emerging 
technologies 
method: review of 
literature and 
information 
 
 
 
 
 
subject could be new, 
emerging and 
established technologies 
with new indications 
to support policy makers 
with timely information 
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All HSS activities consist of 5 sequenced main components:  
Identification is the process of filtering out new and emerging technologies 
which may have an important impact. The challenge is to gather informa-
tion of sufficient quality from a huge quantity of data. In the information 
gathering process sector specific searches – pharmaceuticals, surgical proce-
dures etc. – proved to be most effective for identification. While primary 
sources, basic research journals, provide very early information, secondary 
sources already give hints on medical, financial and social aspects.  
Prioritisation in HSS is the process of decision-making on the technologies in 
which further resources for investigation are to be invested. The target group 
and the data available on specific technologies determine the priority setting. 
The selection is either delegated to experts or is based on agreement by con-
sensus within the HSS or HTA agency. Since this process is susceptible to 
subjectivity, formal prioritisation and ranking along selection criteria are be-
ing used for objectification.  
Early Assessment aims at presenting information on anticipated impact on 
health care and health services. The challenge is to deal with lack of evidence, 
technologies still in development and issues other than health related (or-
ganisational, political, social). Accordingly a balance between timeliness and 
accuracy has to be found. Some quantifiable parameters to assess significance 
of impact are the relevant patient-group, the performance in relation to gold 
standards or the costs over time. 
Dissemination: The impact of HSS is determined by reaching the target audi-
ence and decision-makers that influence regulation or introduction of the 
relevant technologies. Close links to the system and knowledge of the policy-
structure are prerequisites for dissemination and effective implementation. 
Monitoring the assessed technologies and updating the reports with new in-
formation is the final component in the HSS cycle. 
Conclusion: The established Horizon scanning systems are similar in that 
they go through the same processes, but they differ in terms of size, resources, 
operational level, mandate, customers, and organisational embedding and 
therefore there are some differences in methodology of identification, filtra-
tion and prioritisation, assessment, dissemination and monitoring. The most 
obvious difference is that they serve different target groups and therefore pri-
oritise and select different technologies. Additional the weight that is given 
to expert suggestions and the use of implicit or explicit measures for identi-
fication and selection of technologies are characteristics of the different HSS. 
 
 
 
Horizon Scanning 
comprises identification, 
prioritisation,  
early assessment, 
dissemination and 
monitoring  
similar task – differences 
in terms of organization 
and methodology 
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1 Presentation of the project 
This document concerns a work package that is part of the project to set up a 
European Network for Health Technology Assessment – EUnetHTA.  
 
European Network for  
Health Technology Assessment – EUnetHTA project 
In 2004 the European Commission and Council of Ministers targeted Health 
Technology Assessment (HTA) as “a political priority”, recognising that there 
was “an urgent need for establishing a sustainable European network on 
HTA”. In 2005, an invitation to tender by the European Commission was 
answered by a group of 35 organisations throughout Europe, led by the Danish 
Centre for Evaluation and HTA (DACEHTA) in Copenhagen   
(www.eunethta.net). 
The European network for Health Technology Assessment (EUnetHTA) co-
ordinates the efforts of 27 European countries, including 24 EU Member 
States, in the evaluation of health technology in Europe (www.eunethta.net). 
The strategic aim of the Network is to link up public national/regional HTA 
agencies, research institutions and health ministries, thus encouraging ex-
change of information and providing support for policy decisions made by 
Member States (www.eunethta.net). 
Between 2006 and 2008, EUnetHTA intends to develop: 
b an organisational framework for a sustainable European HTA network  
b practical tools to feed into this framework 
to ensure timely and effective production, dissemination and transfer of HTA 
results into useful policy advice to Member States and the EU   
(www.eunethta.net). 
Initially, the project will be co-financed by the European Commission (DG 
Sanco) and contributions from Network members (www.eunethta.net). 
The project is divided into 8 work packages, each with its own milestones 
and deliverables (see www.eunethta.net for details). Work package 7 (WP7) 
is “Monitoring development for emerging/new technologies and prioritization 
of HTA”. 
Since the actual effectiveness and cost-effectiveness of many of the approved 
health technologies cannot be evaluated before broader application under real 
conditions, many countries either release technologies that are not fully as-
sessed or require post marketing follow-up studies. An alternative is the re-
quirement to monitor the use and the outcome of a technology. For this rea-
son some countries have started to set up “registries” or “application-pro-
tocols” in order to keep some health technologies (often surgical or costly in-
terventions) under surveillance before broader diffusion takes place and un-
til final evidence is proven.  
It is the objective of WP 7 to provide tools that enable countries to monitor 
the development of (emerging, new or established) health technologies and 
to share data and results of this monitoring. Another objective is to support 
prioritisation for HTA and for health care decision makers with policy rele-
vant information.  
EUnetHTA was initiated 
by the European 
Commission in 2005  
within the network, the 
efforts of 27 European 
countries are 
coordinated  
 
aim: sustainable 
European HTA network  
co-financed by the 
European Commission  
project is divided into  
8 work packages  
work package 7 refers  
to emerging/new 
technologies  
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To fulfil these objectives WP 7 is divided into two Strands with the follow-
ing aims: 
Strand A: Development of manageable monitoring instruments  
Strand B: Development of frequent information services on new/emerging 
health technologies  
The results of this work can be used within WP6 to show concrete use of in-
formation from selected and monitored technologies by local health policy 
makers in member states. 
 
 
 
work package 7 
comprises two Strands 
(A/B)  
Strand B is about 
information services on 
new/emerging health 
technologies  
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2 Horizon Scanning System (HSS) – An Overview 
All western healthcare systems are confronted with the spread of a rising num-
ber of new health technologies. The development and supply of new health 
technologies is, alongside changing demography and growing expectations of 
the population, one of the great challenges for policy making and research in 
health care[1]. New technologies affect health care systems in various ways 
(improved care, rising costs, changes in treatment). Therefore decisions have 
to be made not only concerning the degree and time of adoption and/or re-
imbursement but also to change current treatment policies (i.e. immuniza-
tion)[2]. To support these decision-making processes with preferably sound 
information about new health technologies, some countries have established 
formal organizational units. They are usually called Horizon Scanning Sys-
tems (HSS), but also Early Warning Systems or Alert Systems[3, 4].  
The aim of this paper is to examine the issue of horizon scanning conceptu-
ally and to point out several differences and similarities between some of the 
organizations working in this field. We focus on specific functions, targets, 
methods and challenges as a means of acquiring a deeper understanding of 
the issue.  
The literature review started out with an extensive list of literature in the field 
of horizon scanning provided by EuroScan[5]. Additionally, internet and hand 
search was conducted, and all member agencies of EuroScan were contacted 
by e-mail to provide unpublished descriptions of their methodology or to give 
any other useful information. Contact information was taken from the Euro-
Scan website. Where personal communication with HSS staff was used as a 
reference, contact details appear in the list of references.  
The development of this report was conducted as a part of the EUnetHTA 
project. 
 
 
 
Horizon Scanning to 
support decision-making 
processes about new 
and emerging health 
technologies  
aim is examining the 
issue and point out 
differences and 
similarities  
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3 Origins of Horizon Scanning Systems  
The issue of horizon scanning first appeared on the agenda in the mid-1980s[4]. 
A Norwegian and a Dutch study had identified health care technologies that 
were predicted to become important to their respective healthcare systems [4, 6]. 
The Dutch study concluded that it is not satisfactory to react to technologi-
cal developments only when confronted with their consequences[3]. Therefore 
the authors called on the government to develop a permanent system for iden-
tifying new health care technologies before they were widely used kind of. 
This led to the first Horizon Scanning System, established in 1985-86 at the 
Dutch Health Council. Since then efforts have been undertaken in several 
countries to develop systems which are capable of providing relevant deci-
sion makers with timely information about potentially important new health 
technologies.  
Currently there are 13 government-funded organizations which undertake 
substantial activities in the field of ‚scanning the horizon’ of [their respec-
tive] healthcare systems. Alongside them several non-profit (ECRI, U.S), for-
profit (Hayes Inc., U.S) or academic (AHFMR, CAN) organizations also op-
erate in the field of horizon scanning.  
The countries with HSSs that are 100 % publicly funded are Canada, Den-
mark, Norway, Sweden, The Netherlands, The United Kingdom, Israel, Spain, 
France, Australia and New Zealand (which co-operate in a network) and 
Switzerland[3].  
Since 1999 these 13 HSS have been collaborating in an information network 
called EuroScan, which is hosted at NHSC, the British HSS. The primary aim 
of EuroScan is to share information on selected emerging health technologies 
or new applications of existing ones in order to address their effects and an-
ticipated consequences[7]. For this reason EuroScan provides a database of 
new and emerging health technologies available only for member agencies. 
Since its start in June 2001 750 topics have been put into database. EuroScan 
additionally offers an open database of different kinds of technology reports 
produced by member agencies. Another aim of EuroScan is to support the 
exchange of information and experience, and research in the field of HSS.  
As a first step towards a broader understanding among the HSS, EuroScan 
members have agreed on a common terminology, classification and under-
standing of their activities[7]. Definitions refer to the object and components 
of HSS. Another aim of EuroScan concerns harmonization of the criteria for 
selecting and prioritizing new technologies (see Chapter 6). 
According to EuroScan, HSS focuses on health technologies that are either: 
b new technologies,  
b emerging technologies,  
b established technologies with new indication or 
b technologies that are part of a group of developing technologies that may 
as a whole have an impact. 
The difference between new and emerging technologies is defined such that 
a new technology is in the adoption phase, has only been available for clini-
cal use for a short time and is generally in the launch or early post market-
ing stages. In contrast, an emerging technology is defined as ‘not yet adopted 
to the health care system’. In the case of pharmaceuticals it will be in phase 
history of Horizon 
Scanning Systems goes 
back to mid 1980s 
currently 13 publicly 
funded HSS + some 
private initiatives 
countries with HSS 
HSS network: EuroScan 
common terminology, 
classification and 
understanding among 
EuroScan members 
emerging technologies 
are not yet adopted, 
new technologies are 
technologies in the early 
phase of adoption 
Horizon Scanning System (HSS) 
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II or phase III clinical trials or perhaps pre-launch. Medical devices will be 
prior to marketing or within 6 months of marketing or marketed but <10 % 
diffused or localised to a few centres[8]. This comes down to a time horizon 
of 0-5 years before introduction[3, 9]. Figure 1 shows the field of work of 
HSS in relation to a stereotyped diffusion process. 
 
Figure 3-1: Field of Work for Horizon Scanning according to Stevens et al. [10] 
Generally, a system which aims at the early identification and evaluation of 
new and emerging health technologies consists of 5 sequenced main compo-
nents[7]: 
1. Identification (& Filtering) 
2. Prioritisation 
3. Assessment 
4. Dissemination 
5. Monitoring. 
The stage of priority setting is sometimes described as a two phase proce-
dure[1, 3, 11]. The first phase is called filtering and comprises the (mainly 
implicit) rough selection of technologies. The second phase, which is the ac-
tual priority setting, comprises of a choice of selected technologies on the 
basis of preliminary evaluations.  
Throughout this report (see also Table 4-1) filtering is assigned to the identi-
fication stage. Douw and Vondeling[3] found in their review of selection pro-
cesses in HSSs that in some systems filtering virtually coincides with identi-
fication. In such systems, HSS staff filter technologies that are deemed un-
important while scanning sources for potentially significant health technolo-
gies. In other systems, filtering is a step that can be clearly distinguished 
from both identification and priority setting[3]. 
Nevertheless, from a functional perspective, filtering appears to be more a 
part of identification than priority setting, even if filtering is an organisa-
tionally distinguishable step between identification and priority setting. Over-
all, the goal of identification and filtering is to generate a list of technologies 
which will be used as the basis for prioritisation, the next step of horizon 
scanning. Therefore, the assignment of filtering to the identification stage 
seems appropriate to further define the term priority setting  
the authors of this 
review assign filtering as 
part of identification. 
For EuroScan Filtering is 
part of prioritisation. 
Horizon 
Scanning 
Emerging 
and New Diffusing 
 
Established 
Development status of technology 
100 % 
50 % 
de
gr
ee
 o
f d
iff
us
io
n 
Origins of Horizon Scanning Systems 
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Despite having the same objective there are some differences among HSS. 
They differ in terms of size, resources, operational level, mandate, customers, 
organisational embedding and therefore in their specific methodology of iden-
tification, filtration and prioritisation, assessment, dissemination and moni-
toring.  
An overview of all current HSS is given in Douw and Vondeling[3] highlight-
ing some differences among them. 
Table 3-1: Horizon Scanning Systems and Their Operating Level, Host Organization, Staff and Costumers 
HSS Country 
National/ 
local/ 
regional Host organization Customer 
Basque office for HTA 
(SorTek) (OSTEBA) 
Spain Regional HTA agency Regional Department of 
Health 
Agencia de Evaluacio´n de 
Technologicas Sanitarias de 
Andalucia (DETECTA) 
Spain Regional HTA agency Regional Department of 
Health 
Sistema de Informacio´n de 
Tecnologi´as Sanitarias 
Nuevas y Emergentes 
(SINTESIS) 
Spain National HTA agency A network of health 
professionals 
Health Council (Gr)  The 
Nether-
lands 
National Governmental advisory 
body 
Department of Health 
Committee for Evaluation & 
Diffusion of Innovative  
Technologies (CEDIT) 
France Local HTA agency Hospital group:  
Assistance Publique-
Hoˆpitaux de Paris (AP-HP)
National Horizon Scanning 
Centre (NHSC) 
England 
and 
Wales 
National Department of Public 
Health and Epidemiology 
at University of 
Birmingham 
Department of Health in 
England and Wales 
Swiss Federal Office of Public 
Health (SFOPH) 
Switzerl
and 
National Federal Office of Public 
Health 
Department of Health 
Norwegian Health Services 
Research Center (NOKC) 
Norway National HTA Agency Norwegian 
Knowledge Centre for 
the Health Services 
Government, health 
professionals 
The Swedish Council on 
Technology Assessment in 
Health Care (SBU-ALERT) 
Sweden National HTA agency Health care professional, 
decision maker at all level 
Danish Centre for Evaluation 
and Health Technology 
Assessment (DACEHTA) 
Denmark National HTA agency Health professionals, 
interested public 
Canadian Emerging 
Technology Assessment 
Program (CETAP) 
Canada National HTA agency Health professionals, 
interested public 
Division of Medical 
Technology Policy (DMTP) 
Israel National Department of Health Department of Health 
Australia and New Zealand  
Horizon Scanning Network  
(ANZHN) 
Australia 
New 
Zealand 
National HTA agency and the 
Australian Safety and 
Efficacy Register of 
New Interventional 
Procedures–S 
(ASERNIP-S) 
HealthPact (Health 
Ministers) 
Source: Dow and Vondeling 2006[3] 
 
despite the same object 
systems collaborating  
at EuroScan differ 
significantly 
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Most of the institutions collaborating at EuroScan operate at a national level. 
Exceptions are the three Spanish HSSs working for regional departments 
and the French HSS operating at a local level. The majority of the HSSs are 
part of an HTA agency. Other forms of organizational embeddings are affi-
liation to a university as in the case of the British NHSC, to a federal insur-
ance office as in Switzerland, to a hospital group like in France or to govern-
mental bodies as in the Netherlands and Israel. Whereas principally all HSS 
could be rated as small units, there tend to be differences in personnel facili-
ties (between 1-9 FTE). These variations could be interpreted as indicators 
of the different relevance of horizon scanning within the healthcare systems. 
What is common to all these HSS is that they are 100 % governmentally 
funded.  
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4 Context of Horizon Scanning Systems 
New technologies bring particular challenges to all healthcare system. These 
are not only in terms of financial burdens due to the fact that all systems 
face budgetary constraints. New technologies can also raise questions con-
cerning managed introduction, reimbursement, organizational requirements, 
changes in medical practice or social and ethical problems[2, 12].  
For this reason the potential HSS target groups are diverse. They can basi-
cally be distinguished into 4 groups, leading to different functional needs. 
These groups are:  
b Decision makers and health service planners 
b HTA agencies 
b Medical professionals 
b Public. 
They all face the overall condition of a growing rate of new health technolo-
gies[13]. Douw et al.[14] illustrated this on the basis of the numbers of new 
drugs that were brought to market in the U.S., which increased from 239 in 
the 1980s to 370 in the 1990s. According to Pharmaceutical Research and 
Manufacturers of America (PhRMA) today there are over 2,000 medicines in 
development[15]. The number of new devices and procedures has also in-
creased. Trindade et al.[16] stated that at least 20 medical innovations of 
some significance appear every week. At the same time there is an increasing 
technology demand from patients and an increasing interest in health care 
issues among the public[17].  
Various trends at the medical industrial market and the public demands were 
observed by ten Velden[18]. Areas of intensified development are thus diag-
nostic technologies, information technologies, less invasive technologies, po-
pulation screening technologies, outpatient and home-care-related technolo-
gies, smaller and more sophisticated medical devices, biotechnology-related 
technologies and organ-replacement-related technologies.  
Both developments, the growing supply of and increasing demand for new 
health technologies, are outpacing health systems’ ability to effectively ra-
tionalize the introduction of new health technologies, because there are most-
ly insufficient data on safety, effectiveness and cost-effectiveness before tech-
nologies are widely diffused[17, 19]. 
Differences between types of target groups can be assumed in respect of their 
specific needs. Decision-makers and health service planners are the main tar-
get group of HSS. As Douw and Vondeling[3] show, decision-makers in 
health care are operating under several – in part contrary – pressures, gener-
ating needs for information.  
Firstly a growing pressure to accelerate decision making on new health tech-
nology can be identified in order to ensure that beneficial technologies are 
made available as quickly as possible. Health technology developments how-
ever, hold the promise of improving care, health service quality and economic 
benefit. Alongside the danger of inappropriate enthusiasm among health care 
professionals in the face of a new technology, public enthusiasm and expec-
tations affected by mass media have an increasing importance[12].  
Secondly there is simultaneously the pressure or expectation to protect con-
sumers of unsafe and ineffective technologies. 
new technologies can 
cause various  
questions … 
… which leads to 
different target groups 
there is a growing rate 
of developments in 
healthcare … 
... especially in some 
areas 
new technologies 
diffuse often on the 
basis of insufficient data 
about their benefits  
decions makers are the 
main target group of 
HSS ...  
... operating under 
several pressures 
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Thirdly a pressure or need to concentrate scarce resources on the most bene-
ficial technologies has arisen. Today, variations in health care practice indi-
cate unnecessary or inappropriate use of technologies. Premature introduc-
tion of new technologies could increase this variation and contribute to inef-
ficiency and inequity in health care[18].  
To manage these situations, decision makers and health planners need above 
all timely and high quality information on new health technologies[3]. The 
fundamental function of HSS is therefore to support policy-makers in con-
trolling and rationalising the adoption and diffusion of new technologies in 
health care practice by providing them with timely information on new health 
technologies and possible consequences for the healthcare system[14].  
In the face of the high political risk related to new health technologies, HSS 
could be understood as a means by which policy makers try to buy time[12], 
enabling them to enhance their planning horizon[4]. To meet these require-
ments, an HSS has to connect policy makers with experts in the field of new 
health technologies (developer, early user, relevant scientific communities) 
and can therefore be understood as a formal mechanism to allow communi-
cation between parties who are in other respects isolated[4].  
In accordance to the diffusion context described above, an HSS may affect 
the diffusion process of new health technologies differently. Carlsson and 
Jørgensen[17] differentiate in this respect between the need to push and the 
need to slow down the speed of the diffusion process.  
The slow down function has traditionally been perceived as the function of 
an HSS, controlling health technologies that are pushed into health service 
by stakeholder or media enthusiasm. An historical example for this kind of 
threat to public health is DES (Diethylstilbestrol), described by Douw et 
al.[14]. DES (a synthetic female hormone to reduce complications in preg-
nancy) was approved for marketing in U.S. 1941 on the basis of several un-
controlled studies carried out by the advocates of the drug. Although 7 con-
trolled studies carried out from 1950 to 1955 showed that DES was ineffec-
tive, it was frequently used worldwide until cases of a rare cancer of the va-
gina appeared which were attributed to DES in the 1970s.  
To push or support a technology is necessary when there are attributes that 
discourage an effective diffusion, irrespective of the relative advantage of the 
technology[17]. This refers to the fact that a technology needs a compatible 
social and political environment to operate effectively[12]. The need to push 
is given e.g. if a new technology has a low degree of compatibility with adopt-
ers’ values, or its’ use and understanding is difficult and requires special quali-
fication. According to ten Velden[18] one of the main purposes of an HSS is 
therefore to support the distinction between technologies which need par-
ticular policies and those which do not. Thus HSS may trigger planning and 
configuring health services or developments of standards and training[17].  
Alongside an inappropriate diffusion process, decision makers may be con-
fronted with controversial ethical, social or political consequence related to a 
new or emerging technology as xenotransplantation or pediatric cochlear im-
plants[12]. Controversies may be triggered by major risks that are difficult 
to assess, profound ethical dilemmas or groups of actors who feel threatened 
in terms of power or resources[12]. HSS is therefore also an instrument to 
increase the awareness and preparation for emerging political or ethical con-
troversies on new technologies. 
HSS function is to 
produce timely 
information on new and 
emerging health 
technologies  
HSS establishes formal 
communication 
mechanisms between 
stakeholders 
HSS can affect diffusion 
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To meet all these functional requirements, the aim of HSS is to provide timely 
reports about important new and emerging health technologies and their an-
ticipated impact on health care and health services before they diffuse too 
extensively[4].  
Based on HSS components, the following work-steps comprise the work of 
HSSs:  
Table 4-1: Components and Work steps of HSS 
Components Work Stepps 
Identification 
(& Filtration) 
b identify new and emerging technologies 
b gather basic information on the technology and its 
applications  
b filter out unimportant technologies as well as 
worthless information 
Prioritisation b select most important technologies for assessment 
(priority setting) 
Early Assessment b perform assessments of selected technologies 
Dissemination b disseminate information on important 
technologies 
Monitoring b monitor assessed technologies 
b update reports if new information is available 
 
An additional aim should also be to evaluate the effectiveness of the HSS it-
self, i.e. to what extent it fulfils its various purposes. Actually there is still a 
lack of evidence concerning effectiveness and efficacy of HSS components 
and the system in general [20-22]. Simpson et al.[23] compared some results 
of prioritisation made by the British NHSC between 1997 and the end of 
1999 with expert opinions on the importance of those technologies 3-5 years 
later. They concluded that NHSC performed acceptably, i.e. they prioritized 
5 of 7 technologies that were rated as important by experts and predicted 80 
of the 110 technologies that were rated as unimportant. As Simpson et al. em-
phasize, such a gold standard is imperfect and complete evaluations of HSS 
have to consider more outcome parameters (e.g. to identify potentially im-
portant technologies that turn out to be ineffective after assessments or tech-
nologies that could have a significant negative impact).  
Alongside decision makers there are other potential target groups for infor-
mation produced by HSS. Firstly, HSS may enable HTA agencies to identify 
and prioritize objectives of further medical research and technology assess-
ment. Earlier identification of technologies could allow cost-effectiveness re-
search prior to marketing and introduction[9]. HSS can therefore be seen as 
the first stage of a comprehensive HTA process. Accordingly most HSS units 
are part of a HTA agency.  
Furthermore, medical professionals may benefit from timely information to 
rationalize practice and by being spared improper expectations. The public 
may also profit by an increased awareness of new technologies and stimu-
lated debate on potentially controversial consequences[17]. 
5 work-steps to scan the 
horizon of health 
technologies  
performance of HSS  
is hardly evaluated  
Horizon Scanning  
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HTA-process 
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Figure 4-1: Functions of HSS 
The specific purposes of a Horizon Scanning System determine to a high de-
gree the particular methods of identification, priority setting, early assess-
ment and dissemination. The specific conditions and challenges which are 
associated with the components of horizon scanning and various differences 
among the member agencies of EuroScan in this regard are the topic of the 
following sections.  
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5 Identification 
The task of this first component of HSS is to identify new and emerging tech-
nologies which may have an important impact on health care service if widely 
diffused. Furthermore, basic information like indication, number of patients, 
cost or clinical effectiveness must be gathered to enable subsequent priority 
setting. To fulfil this task the gap has to be bridged between basic science, 
industry, medical experts and those engaged in horizon scanning[17].  
There are many scientific developments which appear on the horizon but 
never reach market entry. Others, seemingly from nowhere, diffuse rapidly 
within the health care system. The challenge of identification new technolo-
gies is therefore to gather information of sufficient quality from a huge quan-
tity of data. Thus identification may be perceived as the first part of filtering 
before the prioritisation process.  
Data can be obtained from different sources, however all of them are associ-
ated with advantages and disadvantages, dependent on the respective infor-
mation needed. Generally, a distinction can be made between sources appro-
priate for identifying interesting topics and sources that are suitable for gath-
ering further information on interesting health technologies.  
To validate findings and to increase the likely accuracy of any predictions as 
well as the amount of useful information, a combination of sources is rec-
ommended[9, 14]. 
The specific process and kinds of sources used in particular HSS depends on:  
b the purposes of HSS determining what technologies have to be observed 
and what information is required for priority setting 
b resources available 
b individual preferences of local information specialists[14]. 
To assess different identification procedures it is necessary to recognize that 
health technologies differ considerably in terms of their diffusion context. 
Some technologies have to pass regulatory hurdles resulting in a delayed mar-
ket entry, as in the case of drugs which must be approved by FDA and EMEA 
before diffusion into healthcare systems. Other technologies, like surgical 
procedures emerge mostly within medical professions without any formal ad-
mission[1, 24].  
Similarly, the speed of diffusion varies among different types of technolo-
gies[25]. 
In accordance with these different diffusion conditions one can assume that 
distinct information sources will be used for different types of technologies[9], 
i.e. FDA database for drugs and surgical experts for surgical procedures. 
Robert et al.[9] therefore developed a classification of health technologies to 
explore the most useful sources for the identification of new ones. They de-
cided to classify them according to the sectors in which they are most likely 
to originate, highlighting specific sources for identifying. This resulted in 
the following list: 
task: identify new 
technologies and gather 
basic information 
there are several sources 
of various benefits for 
identification 
combination of sources 
is useful 
technology-specific 
diffusion contexts have 
to be considered 
speed of diffusion varies 
as well 
different sources for 
different types of 
technologies 
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Table 5-1: Classification of Healthcare Technologies by Types 
b Pharmaceuticals 
b Diagnostic strategies 
b Procedures 
b Procedural devices 
b Other medical and assistive devices 
b Healthcare settings or treatment delivery systems 
b Information technology  
b New professions 
 
Other forms of classification were presented by Robert et al., e.g. distinguish-
ing between product characteristics (product diversifying/product enhanc-
ing/cost saving) or between origins of the technology (cognitive/mechanical/ 
biological/informational).  
There are also several attempts to classify the huge number of sources offer-
ing information on health technologies. The most common is the classifica-
tion into primary, secondary and tertiary sources, determined according to 
the proximity to the origin of innovation.  
Primary sources provide information from developers or manufacturers like 
patents or FDA licensing applications.  
Secondary sources provide – mostly published – information concerning the 
technology in use from a medical, financial or social perspective, like drug 
information services, conference abstracts, journals, but also expert groups 
or patient interest groups.  
Tertiary sources provide information from other organizations engaged in the 
identification of new health care technologies. These are mainly other HSS 
or EuroScan.  
The separation into primary, secondary and tertiary also highlights a trade 
off between earlier ‘warning’ and greater accuracy of the information pro-
vided. Figure 5-1 presents this trade off, together with the sources which were 
recommended by Robert et al.[9] as the minimum when developing a compre-
hensive HSS. As already indicated, the use of sources is primarily determined 
by the specific purposes of an HSS. 
 
Figure 5-1: Potential Information Sources of HSS  
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Primary sources are likely to provide earlier ‘warning’ but suffer in terms of 
reliability of predictions and detailed data, while secondary and tertiary 
sources are likely to investigate technologies later but with greater detail and 
more accurate predictions.  
In addition, sources face advantages and disadvantages in terms of their dif-
ferent importance throughout the identification process. Blume[12] states 
that technologists, biomedical scientists and clinicians directly involved with 
new technologies have lost some of their ability to estimate the future course 
of an innovation during the last decades because the role of government and 
consumer groups has made innovation and diffusion of health technologies 
more complex and unpredictable.  
Using experts to identify technologies in an open survey is likely to produce 
a long list of potential new technologies but with little detail. On the other 
hand, experts are sometimes the main or sole source for identifying new tech-
nologies, their applications, and their relevance, which is important for sub-
sequent prioritisation. Experts are therefore a key source to any HSS[9, 10]. 
Another advantage of experts is that data can be collated quickly and cheaply. 
However, a central and challenging question is who is to be classified as an 
expert and how to access them in horizon scanning. 
The advantage of regulatory bodies like the FDA and the EMEA for drugs or 
the EU marketing approval for medical devices (CE markings) is the high 
number of hits possible and in the case of drugs the predictable time hori-
zon. Additionally data via internet is easily and cheaply accessible. The high 
rate of hits makes it simultaneously difficult to identify more important can-
didates.  
The benefit of industry-related sources depends on the time horizon. It is as-
sumed that information concerning long-term planning of future technolo-
gies is more easily accessible than information concerning a product ready to 
market[17]. The main barrier for reliable information from companies might 
be the commercial sensitivity of such data. Nevertheless collaborations with 
suppliers of health technologies are important for the work of HSS but also 
may involve conflicts of interest. EuroScan has therefore developed some 
guidelines for collaboration between industries and individuals in HSS[26].  
General scientific journals like Nature posses the same disadvantage as pri-
mary sources, informing too early and possibly unreliably. Specialist medi-
cal journals are in contrast one of the best sources for identifying diagnostic 
strategies, procedures and other medical and assistive devices but need huge 
time resources due to their high number[9]. When using tertiary sources, one 
must consider that different priorities may be applied by these organizations. 
Resource restrictions and the huge quantity of data instigate the use of the 
internet for identification [13, 14, 16, 27]. It was observed that the control of 
the huge amount of data on new health technologies offered by a great num-
ber of web sites is the biggest challenge to HSS using this media. All studies 
present various web sites of different importance. However, they emphasize 
that, to perform effectively and efficiently, it is necessary to develop specific 
internet search strategies. Such strategies have to depend on categories of 
technologies and the specific kind of information needed. Appendix I lists 
several important web sites mentioned by these studies and staff of HSSs. 
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this applies to 
developer, …  
… experts, …  
… regulatory bodies, …  
… companies, … 
… journals, …  
... and the internet 
Horizon Scanning System (HSS) 
24 LBI-HTA | 2006 
5.1 Differences of Identification among HSS 
Generally there are a lot of similarities of identification methods but also some 
differences among EuroScan member HSS, mainly reflecting differences of 
purposes and resources available.  
Firstly there are differences regarding the scope of scanned technologies. The 
majority of HSS consider all kinds of technologies and specialities. Excep-
tions are the systems of Norway, Australia and New Zealand, the Basque and 
Andalusia agencies.  
The Norwegian agency is constrained by disease considering only cancer treat-
ments[28]. Others, by contrast, focus on different types of technologies. The 
Australia and New Zealand Horizon Scanning Network (ANZHN) observes 
no drugs but directs its attention with NET-S particular towards surgical 
health technologies (ANZHSN Homepage). OSTEBA (Basque) also excludes 
drugs and focus on devices and procedures[29]. 
Secondly there are differences in sources used for identification. The major-
ity of HSS combine the scanning of various sources like journals, websites 
and other HSS and EuroScan, with active (i.e. permanent co-operation) or 
passive (i.e. information on inquiry) use of experts and health professionals. 
A Special case in this respect is the Israeli HSS, which works on the basis of 
a list of 400 candidate technologies for the basket of publicly funded health 
technologies[30], the Norwegian HSS which uses tertiary sources and a clini-
cal network exclusively, the Spanish SINTESIS, which mainly uses expert 
suggestions and the French CEDIT, which identifies potential topics mainly 
by requests from representatives of a huge organization of hospitals in the 
Paris region[31].  
Thirdly there are a few features concerning the method of identification. The 
Danish HSS has at one time developed a specific Internet search strategy for 
new health technologies in oncology. 
The British NHSC collates the scanning of sources with a speciality based 
work program to ensure an in-depth investigation in every medical speciality. 
The SINTESIS attracts attention because it has developed a complete inter-
net and intranet-based program to manage the issue of horizon scanning. 
According to Douw and Vondeling[3] a subsequent filtering of identified but 
trivial technologies to narrow down their number is undertaken within two 
systems using individual experts or groups of clinical experts. For this pur-
pose, these systems use a form with predefined questions concerning the nov-
elty of the technology, the time horizon of introduction and the likely impact. 
In the other systems, which declared that they undertake filtering, this proc-
ess is completely implicit.  
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6 Priority setting 
Through identification HSS usually finds a certain number of health tech-
nologies that are appearing on the ‚horizon’ of health care service. As re-
sources are limited the subsequent task of HSS is to decide in which of those 
technologies further assessment resources are to be invested. This task is la-
belled as priority setting and constitutes the second component of HSSs. Pri-
ority setting in HSS differs to some extent to the similarly labelled issue of 
priority setting in health care. The objective of the latter is to select the tech-
nologies which should become part of healthcare basket.  
In contrast, the objective of priority setting in horizon scanning can gener-
ally be described as to define the potentially most significant new and emerg-
ing technologies[3] in order to invest the scarce assessment resources on those 
technologies.  
Obviously the term ‚most significant’ is ambiguous and requires further ef-
forts in operationalization. Selection criteria fulfil the purpose to define the 
characteristics of a new or emerging health technology that indicate its sig-
nificance. Generally, in this stage of horizon scanning a choice will be made 
whether a technology will be assessed or onwardly observed (monitored)[18].  
It is not surprising that selection criteria differ among HSSs, albeit slightly, 
reflecting differences in terms of values, target groups and specific purpose. 
Before criteria used among HSS are presented in more detail, some comments 
shall clarify the general conditions and constrains of the priority setting issue 
for new and emerging health technologies. 
 
 
6.1 Conditions of Priority Setting  
Three factors seem to affect the selection of criteria and the mode of decision 
making to define candidates for profound assessment. As Figure 6-1 shows, 
priority setting depends on the target groups and the data and resources avail-
able.  
 
Figure 6-1: Factors Determining Priority Setting in HSS 
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Firstly, priority setting on new and emerging technologies is fundamentally 
dependent on the target group(s) of the prevailing HSS[17]. The definition of 
target group(s) determines the specific purpose of an HSS. This defines si-
multaneously the most interesting aspects of new and emerging technologies. 
According to the pilot study for the Swedish SBU Alert, only 10 % of the 
target groups were interested in all the technologies assessed[27]. Different 
interest-structures among users of health technology assessment (HTA) are 
presented by studies examining the different use of such reports. As Luce 
and Brown[32] observed for the U.S., hospital based decision makers are 
particularly interested in financial or economic aspects of a new technology, 
whereas decision makers in payer organisations focused more on evidence of 
clinical and cost-effectiveness. In contrast to that, political decision makers 
might be more interested in social, legal or ethical consequences e.g. technol-
ogies that affect a small number of patients but require administrative deci-
sions[33]. Others such as strategic planners might be interested in detailed 
information about those technologies with the most organizational impacts. 
For clinicians, on the other hand, the potential patient outcome might be most 
important.  
Secondly the setting of priorities for Horizon Scanning is largely constrained 
by the data available. Thus the data available at the time of decision making 
defines the possible range of selection criteria. It is, for example, more diffi-
cult to use ‚value for money’ as a criterion, as long as there is no sound data 
on the effectiveness and costs of a technology[3, 11, 34]. Obviously the avail-
ability of data increases with the stage of development and diffusion. In this 
context the specified time horizon of the HSS is of importance. Therefore, 
priority setting faces also the known dilemma of accuracy and timeliness.  
Thirdly, efforts towards the issue of priority setting in HSS are limited by the 
resources available. This refers mainly to staff time for gathering informa-
tion on technology candidates. For that reason there is a link between avail-
ability of resources and that of data. Resources are furthermore necessary for 
the process of decision making, applying the selected criteria Work time – 
either of external experts or HSS staff – also increases with the number and 
complexity of the criteria and with a more explicitly organised decision mak-
ing process [33].  
The extent to which the priority setting component of an HSS fits its goals 
can be retrospectively described in terms of outcome parameters known for 
diagnostic tests[23]. The primary goal of priority setting in HSS is to select 
those technologies for further assessment that will truly become most signifi-
cant (in terms of selection criteria) to a health service. This can be described 
as sensitivity or the extent of true positive or avoidance of false negative pre-
dictions. As assessment resources are scarce, it is secondly important to avoid 
assessments of less important technologies or false positive predictions. The 
extent of false positive predictions is incorporated in the term specificity.  
However, specificity is a precarious outcome parameter because, thanks to 
the work of HSS, technologies may possibly not become as important as they 
would be without assessment triggered by HSS. Therefore some prioritized 
technologies that appear ex post as not so significant and must be counted as 
true negative predictions owe this to the work of an HSS. To put it in a nut-
shell, good performance of prioritisation comprises not only the selection of 
those technologies which truly turn out to be most significant, but also those 
which would gain unjustified significance or inappropriate use without as-
sessment. 
target groups define the 
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6.2 Differences of priority setting among HSS  
Prioritisation of technologies is not used in every HSS, either. Systems which 
exclusively assess technologies on request do not need this stage. This is the 
case in the Israeli and French systems.  
 
6.2.1 Process of Priority Setting 
Concerning the process of priority setting Douw and Vondeling highlight 
that all HSS select technologies on agreement by consensus – either by the 
HSS or the HTA agency that hosts the HSS or it is delegated to experts. The 
process of prioritisation in HSS is therefore more susceptible to subjectivity. 
According to Douw and Vondeling[3] subjective means that it is not clear if 
all criteria are taken into account and if the same process is followed for each 
technology. The description “an on-back-of-our-mind exercise”[3] typifies 
this process well.  
As Douw and Vondeling[3] note, two HSS tried to objectify the selection pro-
cess by using formal priority setting methods, where criteria were scored and 
weighted and a final ranking was achieved on the basis of decision rules. 
Both systems stopped using those formal methods, because the associated ef-
forts exceeded their means[3]. Up to now the specific conditions of priority 
setting in HSS, particularly the limited availability of data and correspond-
ing resources, complicates the establishment of an explicit and transparent 
selection process. 
Nevertheless, there are some tools capable of enhancing the accountability of 
the selection process. Besides the use of explicit criteria it might be advanta-
geous to operationalize, if possible, individual criteria to improve common 
understanding. Another tool would be a formal checklist of the selection cri-
teria and their indicators, which is intended to enhance the likelihood that all 
criteria are taken into account. Finally the documentation of the decision 
process might substantially enhance accountability and transparency.  
The more implicit the selection criteria are used, the more important other 
factors may become for priority setting on new and emerging health tech-
nologies that do not necessarily correspond to the selection criteria in use. 
According to qualitative case studies on the issue of priority setting in health 
care, decision making under such circumstances is affected by the following 
factors[35]:  
b organizational context in which the decisions are made 
b people who make the decision 
b factors they consider 
b specific reason for the decisions 
b characteristics of the process of decision making (procedure, appeal 
mechanisms). 
The more implicit the prioritisation, the more likely are the results biased by 
influences concerning the factors which do not reflect the chosen selection 
criteria. The latter factor refers to the special relevance of the chairman for 
decision making within a collective player. The significance of the chairman 
in collective bodies for decision making is also addressed in the study by 
Douw and Vondeling[3]. 
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prioritizes technologies 
those, which prioritize, 
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The second factor highlights the fact that the more implicit the process of de-
cision making, the more important individual knowledge and experience in 
fields of medicine, HTA and health care system becomes for the sensitivity of 
the HSS[33].  
 
6.2.2 Selection Criteria in Use 
Selection criteria in HSS define which characteristics of a new and emerging 
technology are crucial to trigger further assessment efforts. According to 
Douw and Vondeling[3] the majority of the examined HSS use selection cri-
teria explicitly, which means that they are internally documented. Hence 
only one system prioritizes implicitly, i.e. without defined criteria, whereas 
two systems declared that they use explicit and implicit criteria.  
Among those HSS using explicit criteria somehow, extensive congruencies as 
well as specific differences regarding the composition of criteria can be ob-
served. EuroScan developed a list of criteria comprising the central criteria 
used by its member agencies. Table 6-1 displays the criteria, which are in 
patches further specified by EuroScan. 
Table 6-1: Selection Criteria formulated by EuroScan  
Priority setting criteria Specifications 
regarding health benefit major uncertainties 
regarding cost-effectiveness 
innovative therapy for a disease or disorder with 
no satisfactory standard treatment 
a new, potentially more effective therapy, 
measured by relevant outcomes, than standard 
treatment 
health benefit if diffused 
widely  
a new therapy with significantly fewer known 
side effects or long term adverse effects than 
the standard treatment 
potential for inappropriate 
diffusion or use of the 
technology 
 
because of moderate to high unit costs 
because of patient numbers 
Major cost impact 
because of service re-organisation requirements 
other major impacts like staff retraining needs 
significant legal, ethical, 
political, environmental or 
social issues with regard to 
the use of the technology 
 
 
As Douw and Vondeling[3] show, costs related to an emerging technology are 
the most frequently considered characteristic among HSS (Table 6-2). Simi-
larly broad consideration is given to the possible health benefit or uncertainty 
on this issue as criteria to legitimate further assessment. These leading crite-
ria are followed by the organizational consequences of a technology (73 %) and 
fears in the diffusion rate as well as ethical, legal or social issues (both 64 %). 
Other criteria used by a number of HSS were the number of patients (55 %), 
the innovativeness of the technology (36 %), cost-effectiveness (27 %) and se-
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verity of illness (18 %). The fact that only a minority use cost-effectiveness 
seems to affirm the assumption that this indicator is mostly not yet available 
for this issue.  
Table 6-2: Most frequently used Selection Criteria among EuroScan Members[3] 
 1. Costs 
 2. Health benefit and/or uncertainty according to health benefit 
 3. Organizational consequences 
 4. Rate of diffusion 
 5. Ethical, legal, social issues 
 6. Number of patients 
 7. Innovativeness 
 8. Cost-effectiveness 
 9. Severity of illness 
 10. National policy relevance  
 
Douw and Vondeling[3] observed additionally eight other criteria, mainly 
unique to one HSS, reflecting specific fears concerning new technologies. The 
British NHSC e.g. considered if a technology is of policy relevance or rather 
concerns clinical guidance or government priority areas. The Danish HSS 
considered the grade of interest of investors, clinical experts and decision 
makers for a new technology. 
The number of selection criteria used varies highly, ranging from three to 
thirteen. However, there are no explicit decision rules or weighting tools used 
among HSS which would assign different importance to the selection criteria 
of an HSS. Such an approach would only be preferable as long as the weight-
ing criteria reflect the needs of the target group(s). Therefore selection crite-
ria are not an instrument for managing priority setting in HSS, but instead 
for facilitating a systematic and informed decision making process. 
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7 Early Assessment and Monitoring 
The task of early assessment is to gather and present information on a new or 
emerging technology, that was identified – whether by formal identification 
and priority setting or by commission – as potentially relevant for future 
health care service.  
Stevens et al.[10] noted that the evaluation process accompanying the intro-
duction of new important technologies appears to follow a pragmatic five-
staged sequence of events, which illustrates the area of early assessment 
(Figure 7-1, Table 8-1).  
 
Stage Data 
1. Primary data sufficient for launch or licensing, assembled by the manufacturer 
or pharmaceutical company 
2. Brief report on the advantages and disadvantages of the new technology, who 
might prescribe it, and the need for research 
3. Rapid systematic reviews (based on published and unpublished primary 
research) and cost effectiveness modelling (making various assumptions on 
cost and longer term outcomes) 
4. Longer term systematic review, Cochrane review or other systematic review  
5. Pragmatic randomised controlled trial (the result should be set in the context of
updating existing systematic reviews  
Figure 7-1: Area of Operation of Early Assessment  
The aim of early assessment is to produce timely reports on such technologies 
and their anticipated impact on health care and health services[4].  
These reports comprise first of all descriptions and explanations of the tech-
nology in question. This is followed by information concerning the clinical, 
economical and societal impacts.  
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7.1 Conditions of Early Assessment  
In fulfilling this purpose, HSS have to deal with a number of issues. Based on 
the literature reviewed the following three can be differentiated:  
b lack of evidence 
b technology development (change of its subject) 
b consideration of non health-related issues  
(political, social, organisational). 
It is quite natural that the earlier a technology is in its life-cycle the less in-
formation on the technology is available. At the same time, it is advisable to 
begin assessment as early as possible, because the earlier in the diffusion pro-
cess a technology is assessed, the easier it might be to start assessments un-
distorted and to influence decision making and further diffusion[17, 36]. 
Early assessment thus faces the same dilemma of all Health Technology As-
sessment (HTA), to balance timeliness and accuracy. In the case of early as-
sessment the timeliness of such information is associated (bought) with less 
accuracy of data.  
Another challenge for early assessment is that its objective is a moving entity. 
Technological changes are possible between first identification and market 
entry, but also after introduction. As Gelijns and Rosenberg[37] stated, health 
technologies may change in terms of indication or patterns of application 
through an iterative interaction between users and manufacturers. These 
changes often help to improve outcome or reduce costs but may invalidate 
the results of previous evaluations[38].  
Given the limited availability of sound information and the dynamics of tech-
nological change, early assessments must be perceived as part of an iterative 
evaluation process. Its rationale is to present the best available information at 
each stage of this iterative process[17]. To steer this process, it is important 
to monitor assessed technologies. Monitoring is therefore to be rated as an 
integral part of early assessment. Ideally reassessment should be carried out 
when sufficient new data is available or when a technology has changed 
enough[4, 36]. The issue is here to find reliable triggers or thresholds.  
The third issue of producing early assessment is not only to assess in terms 
of clinical effectiveness, costs or cost-effectiveness, but also according to the 
political, social and organisational consequences. As Rosen and Gabbay[39] 
argue, the extension to these aspects entails complex methodological prob-
lems. According to Carlsson and Jørgensen[17] it is essential to involve the 
social sciences in early assessment to incorporate the perspectives of patients 
and consumer.  
Broader understandings of these three challenges to early assessment and ap-
proaches to better deal with are presented separately below.  
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7.1.1 Lack of Evidence 
Usually no randomised controlled trials or even systematic reviews are avail-
able when horizon scanning systems start to assess emerging technologies. 
It’s therefore seldom possible to fully analyze effectiveness or cost-effective-
ness[17]. According to clinical effectiveness, expert opinions or other meth-
ods from a lower level of evidence are the basis of early assessments[4].  
The persons possessing the greatest knowledge are the researchers who have 
contributed to the development of the technologies, or medical experts in the 
field. However, it must be assumed that anyone who has participated in the 
development and early testing work is especially optimistic about the bene-
fits and the further usage of the technology in question[27, 40]. 
As reliable data on effectiveness is normally unavailable, early assessment 
concentrates on the topic to aggregate the available data, which is necessary 
for a future complete assessment. Information that is available earlier to con-
sider cost-effectiveness is for instance costs or alternative treatments. Efforts 
in preliminary economic evaluation may also help to clarify what the impact 
of a new technology might be, what effectiveness it must reach or where cri-
tical thresholds of efficacy in relation to extra cost lie[17, 41].  
A general assessment of the impact of an emerging technology on a health 
care system needs more than effectiveness or cost-effectiveness. Blume[12] 
specifies a few quantifiable parameters capable of assessing the significance 
of an emerging technology for a healthcare system. These are: 
b For which patients will it work?  
b Will it be more cost-effective than existing procedures? 
b What is the spread of costs over time likely to be? 
Indeed, these parameters are potentially more difficult to estimate than it ap-
pears at first glance. A technology that promises cost saving and improves 
quality at an individual level may lead to an increase in total expenditures 
caused by growing use of the technology[37, 42]. Predictions of other outcome 
parameters like length of stay or work time saved are also difficult. Handling 
such complex estimations requires a number of theoretical steps.  
One example of such steps is the framework for predicting the impact of new 
health technologies on average length of stay, developed by Simpson et al.[43]. 
The framework distinguishes three main categories of mechanisms affecting 
the average length of stay. According to this, a technology may influence the 
length of stay directly, through its influence on patient characteristics, and 
through the impact on organization and clinical practice (Figure 7-2). Each 
new technology somehow associated with inpatient stay could thereby be con-
sidered separately according to these categories by early assessors.  
 
Figure 7-2: Impacts of a New Technology on average Length of Stay[43]  
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The development of such prediction frameworks, by identifying key variables, 
ensures that various facets of a new technology are taken consistently into 
consideration[41, 43].  
Other approaches suggested for managing the ‘data gap’ of early assessment 
are “retrospective forecasts”, where the forecasts of a new technology are com-
pared with actual evidence or rough preliminary estimates concerning the re-
sults from major clinical trials to compare former predictions and actual re-
sults[17, 41].  
A different approach would be to equip HSS with the mandate and funding 
to collect the data which is not available.  
However, no methodological approach is able to completely eliminate the un-
certainty of early assessments. When decisions must be made on the basis of 
early assessments there is always the risk of recommending a technology that 
later proves to be unfavourable or of rejecting a technology that later proves 
to be favourable[17].  
Therefore the presentation of early assessments has to reflect the nature of 
uncertainty, labelling possible variations of key variables and the methods 
used[27, 41]. Basically the variety of bias requires a systematic and explicit 
procedure in early assessment. To manage the danger of unreliability from 
primary sources, the Swedish HSS SBU-Alert lays down that assessments must 
be made with reference to existing data, documented experience, and general 
considerations. The use of primary data is merely tolerated in exceptional 
cases[27]. Furthermore, SBU-Alert reports state the evidence level on which 
their statements are based to communicate the extent of uncertainty concern-
ing their messages.  
As always, there are various differences among health technologies according 
to early assessment. Some technologies are easier to assess than others. Es-
pecially those technologies that present a substitute or a replacement for ex-
isting technologies or that are already established but are to be developed for 
a new application are easier to assess[17].  
The lack of evidence is an unavoidable condition of early assessment. There-
fore early assessments have to be considered as an iterative process compris-
ing assessment, dissemination, monitoring and reassessment components[17].  
 
7.1.2 Technology Development 
As the time horizon of horizon scanning systems spans up to 5 years before 
introduction, early assessment has basically to deal with technological devel-
opments. Even after introduction, health technologies are by no means stable 
entities. Instead, introduction constitutes the beginning of a prolonged proc-
ess of redesigns and improvements triggered by feedback mechanisms[37].  
In consequence, it has to be added that the earlier an assessment is conducted, 
the greater is the probability of irrelevant data (For example, through further 
developments of the technology or changed indications for its use)[38].  
The basic challenge for assessors is the appearance of different variations of one 
generally innovative treatment approach, generating a form of treatment fam-
ily[44]. This concerns particularly devices, which are subject to frequent modi-
fications in design and use after licensing. Generally it is easier to manage the 
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development issue for highly regulated health technologies like pharmaceuti-
cals, as regulation hurdles require a more formed? kind of technology[36].  
Greer[45] distinguishes dynamic technologies from formed technologies by 
considering their different diffusion patterns. According to her, formed tech-
nologies are more or less completed products such as CT scanners or automa-
ted blood analyzers. In contrast, dynamic technologies develop as they diffuse. 
Greer names coronary surgery, fiberoptic or neonatal intensive care as exam-
ples for those technologies. As formed technologies have stable characteristics, 
allowing concluding assessments, their diffusion happens faster and is more 
predictable compared to dynamic technologies.[45].  
Lilford et al.[44] have proposed a modified type of trial – the ‘tracker trial’ – 
which would enable researchers to begin collecting high quality randomised 
trial data, although there are various examples of the new type of technology 
in progress. The idea of the tracker trial is to compare the standard treatment 
at the beginning with all available versions of the innovation in question and 
to modify experimental subgroups, protocols and research questions as the 
trial proceeds. This would comprise the inclusion of new promising applica-
tions and the exclusion of versions which show significant disadvantages. The 
disadvantage of the tracker approach is that it would require more complex 
and resource-intensive commissioning, management and analysis. Although 
this approach seems broadly disregarded, it is also clear that the challenge of 
the technological development of new health technologies requires a multifac-
eted approach and more complex research efforts on trial management[1].  
HSS should take into account the possibility of important developments not 
only before introduction, but also afterwards. It would be advantageous to 
identify different stages of development of a health technology with respect 
to the possibility of significant changes. As Mowatt et al.[36] argue, such a 
theoretical model of a linear process towards technological stability is only ap-
propriate for highly regulated technologies. Less regulated technologies may 
develop in a more complex manner during diffusion. This makes it more dif-
ficult to identify phases of technological modification.  
The issue of changing developments additionally aggravates the object of mo-
nitoring and reassessment, as reassessment is not only indicated when new 
important data is available, but also when a technology has changed to some 
extent. The question is again, what are appropriate indicators for starting re-
assessment[36].  
 
7.1.3 Socio-Political Issue 
The purpose of horizon scanning systems is to provide timely information 
not only to medical professionals, but also to decision makers and the inter-
ested public. These aims necessitate broadening the focus for information to 
issues that are not directly related to health care service but rather to its so-
cietal embedding. Next to information on the possible impact of a health tech-
nology on health service in terms of costs, patient group, effectiveness or al-
ternative treatment, HSS should also focus on social, organizational and po-
litical (comprising ethical and legal questions) issues[17, 39]. 
Such a claim sounds reasonable and understandable, but operationalization 
is difficult to deal with. A main problem is again the lack of sound data be-
fore a new technology has come into use in everyday health care. It may be 
complex to assess or even measure the organizational impact (i.e. concerning 
basically, one can 
distinguish dynamic 
technologies from 
formed technologies  
technological 
developments concerns 
trial management as 
well  
identification and 
theoretical modelling of 
stages of development is 
restricted 
monitoring should be 
sensitive to new data as 
well as to technological 
changes 
early assessment 
comprises 
organizational,  
social and political 
consequences of health 
technologies 
the problem is to 
operationalize these 
issues ... 
Horizon Scanning System (HSS) 
36 LBI-HTA | 2006 
staff time saved) as this depends highly on local circumstances and is hard to 
generalise[39]. Also ethical and social concerns may change as patient groups 
or applications of a health technology change during early adaptation.  
The specific problem of this task is that the ordinary information sources for 
health technology assessment might be unable to cope with this challenge. 
Early Assessment principally relies on scientific and clinical literature and on 
the views and judgements of well-informed senior professionals[12]. Carlsson 
et al.[27] emphasize that medical experts may be unsuitable to assess effects 
on health care organization or economy and researchers may not perceive the 
ethical problems of relevant groups within society.  
The task is therefore to consider, alongside scientific feasibility and clinical 
usefulness, desirability or potential consequences in politics and society. Such 
an approach requires consideration of different perspectives, especially those 
of users and parties possibly affected.  
Early assessment needs therefore the involvement of scientific expertise in the 
field such as political science, sociology or law. Such an approach leads to a 
number of consequences. The more and deeper an early assessment consid-
ers these not (directly) health related issues, the more informational benefit 
for the specific case but the less the transferability to different contexts (e.g. 
countries, patient groups) is to be expected[12]. 
As Rosen and Gabby[39] indicate, this may lead to concerns among assessors 
about a dilution of the well-known data-orientated methodology with the more 
diffuse study of organisational systems or ethical doubts.  
 
 
7.2 Differences in Early Assessment 
Differences in early assessments among HSS can be identified concerning the 
format in which information on new and emerging technologies is produced 
and the style of assessments. The latter appears to be essentially dependent on 
who is commissioned to make the assessment. According to Douw et al.[11], 
who compared assessments of CETAP and SBU, assessments written by clini-
cal experts are more detailed, are clinically oriented and require some insights 
into medicine. If the assessments are written by HSS staff, reports might be 
more concise and understandable even for non medical target groups.  
HSS also differ in terms of size. Some produce short reports without dedi-
cated recommendations, like the Swedish, the Danish or the Norwegian. Oth-
ers, such as the Dutch, the Israeli and the Swiss HSS, produce partly com-
prehensive reports to enable profound decision making. The French CEDIT 
again produce early assessments in the format of dedicated recommendations.  
The Canadian HSS and the HSS of Australia/New Zealand state that they 
generate different formats of emerging technology messages. Whereas the lat-
ter published short prioritising summaries as well as more detailed horizon 
scanning reports, the Canadian CETAP produces a bulletin on new and emerg-
ing technologies, a newsletter and a list of emerging drugs.  
 
... and to find  
adequate sources 
other perspectives must 
be considered, …  
… which require 
involvement of different 
scientific expertise … 
... and methodological 
approaches  
early assessments differ 
in terms of format,  
style and size 
 LBI-HTA | 2006 37 
8 Dissemination and Implementation 
Having identified, prioritized and subsequently assessed new or emerging 
technology, the final stage is to disseminate the findings. The dissemination 
and implementation of reports about emerging technologies faces a special 
challenge in so far as the findings so early in the life-cycle of a technology most 
likely involve great uncertainty.  
It must also be considered that early messages concerning a new technology 
may sometimes be commercially sensitive and require therefore restricted dis-
semination as in the case of the British NHSC[46].  
As long as the available evidence does not allow the deduction of any recom-
mendations on the introduction of a technology, the aim of these reports should 
be to enhance the awareness of the development of the technology and to in-
fluence further research efforts.  
As Carlsson et al.[27] noticed, the development of internet HSS today enables 
their dissemination needs to be arranged according to emerging technologies 
with the need to update information quickly and often. 
The specific dissemination strategy is essentially determined by the relevant 
customer or target group of an HSS[17, 21, 39, 47]. As Hailey et al.[33] note, 
it is also decisive for the benefit of horizon scanning systems that decision 
makers have appropriate machinery for using information of this sort[33]. If 
horizon scanning is to facilitate and rationalize the provision of healthcare it 
is therefore necessary to have an organization to receive and react to such in-
formation[27, 38]. 
Furthermore the literature highlights the characteristics of the message and 
the timing of dissemination as important factors for the success of dissemi-
nation and implementation[21, 47].  
 
 
8.1 Target Group(s) 
According to Carlsson and Jørgensen[17], the potential target groups of hori-
zon scanning reports are regulatory bodies, policy makers, research funding 
agencies, health insurance organizations, physicians, other health profession-
als, hospital administrators, patients’ organisations, the public and perhaps 
industry.  
As Mowatt et al.[21] stress, it is initially important to direct horizon scanning 
messages at those target audiences that have been identified as powerful in 
influencing introduction and diffusion.  
It may also be necessary to consider that the respective powerful target audi-
ence depends on the type of technology[48] and the purpose of the messa-
ge[21]. It therefore makes a difference if the technology is a highly regulated 
new drug or a non-regulated new procedure, if it recommends the stopping 
of the use or the promotion of the technology.  
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Regarding the effectiveness of alternative dissemination strategies, the Eur-
Assess Subgroup[47] observed that there is some evidence about effective dis-
semination strategies to change the behaviour of health professionals, but 
only limited evidence concerning decision makers or patients. Different pat-
terns of incentives as well as social or cultural factors make it impossible to 
recommend a universal approach. 
Nevertheless, it is regarded as worthwhile for the dissemination of horizon 
scanning findings to establish close links to the system for knowledge dis-
semination and implementation[1] as well as to the information system with-
in the policy-making structure[33].  
As opinion leaders (i.e. well respected peers) might play a big role in these 
systems, it is important to identify and reach them[39]. Alongside the infor-
mation needs of the specific target groups, other determinants of their prac-
tice and competing resources of information should be considered before dis-
semination[47].  
 
 
8.2 Characteristics of the Message 
The source, content and style of emerging technology reports may also influ-
ence its impact. As Rosen and Gabby[39] emphasize, clinicians and manag-
ers rate the findings of health technology reports differently to how the HTA 
or HSS might do.  
Whereas assessors are more focused on methodological stringency, target au-
diences pay more attention to the credibility of the researchers or the types 
of outcome associated with the technology (e.g. risk or benefit). Both, HSS 
and HTA agencies have to consider the complexity (i.e. the knowledge back-
ground and language they presuppose) and the quantity of information in 
their messages[17, 21]. 
 Of equal relevance is the credibility and appreciation of the source among 
target group members for the acceptance for the message[39]. Of particular 
importance is therefore the plausibility of the independence of the HSS con-
ducting early assessments[48]. 
 
 
8.3 Time of Dissemination 
In addition to appropriateness and selectivity of the message concerning the 
target group, the timing of dissemination is termed as a key factor for its im-
pact[47]. The task in this respect is to attune the process of dissemination to 
the process of decision making on a new technology. Potentially influential 
research may be ignored if it matches the decision making process too early 
or too late[39, 48]. The challenge as to the timing of these messages is to con-
nect the need for flexibility (e.g. if a policy maker urgently needs quick in-
formation) with the necessity of a sound scientific foundation for such mes-
sages[17].  
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8.4 Differences of Dissemination among HSS 
As stated above, dissemination activities depend primarily on the specific 
target group(s) of an HSS. On the basis of the differences among HSS con-
cerning their customers presented in Table 1, a distinction can be made be-
tween three types of target groups (Table 8-1). 
Table 8-1: Types of Target Groups for HSS 
Department of Health  
(national, regional) 
Health  
Professionals 
Systems without  
dedicated customer 
NHSC (GBR) 
SorTeK (ESP) 
DETECTA (ESP) 
ANZHN (NZL/AUS) 
Health Council (NED) 
DMTP (ISR) 
SFOPH (CH) 
CEDIT (FRA) 
SINTESIS (ESP) 
NOKC (NOR) 
SBU-Alert (SWE) 
DACEHTA (DEN) 
CETAP (CAN)  
 
In the first group, national or regional departments of health are the custom-
ers of horizon scanning messages. The second group comprises those HSS 
which primarily inform health professionals about new and emerging tech-
nologies. HSS which have not got a dedicated customer for their early as-
sessments form the third group.  
Although the first two groups might have a specific target groups, the prod-
ucts might also be available to a wider audience, as a number of the  
HSSs publish their assessments on the web (e.g. CEDIT, NHSC). Some of 
the assessments are also made publicly available through the EuroScan web 
site[49]. 
On the one hand systems without a dedicated customer might have the great-
est need for developing a specific dissemination strategy as there is no direct 
link to the target groups. On the other hand Douw and Vondeling[3] exam-
ined different ‘risk groups’ in terms of priority setting among HSS in Euro-
Scan and found that those systems which do not have a customer but inform 
a wide variety of decision makers, experience only a moderate need for pri-
ority setting. This was explained by the fact that there is not a lot of pres-
sure/demand from the outside[3].  
However, the missing direct link to the customers in such systems demands 
the establishment of certain communication channels. One example docu-
menting such efforts is the Canadian newsletter ‘Technology Update’[50]  
Studies examining the impact of HTA messages emphasize that simply pub-
lishing is often not enough[48, 51]. Therefore, some HSS undertake efforts 
to communicate their messages more directly to people viewed as important. 
The Swedish SBU Alert, for example, established a network of nearly 4,000 
people working in the healthcare sector, who receive new assessments or re-
visions by e-mail[52]. Likewise, SorTek at OSTEBA is working on establish-
ing a Spanish network to provide information to the Spanish Health Service 
and the Ministry of Health [29]. 
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Appendix 
List of several important web sites to identify new and emerging health technologies (accessible: 28.08.06) 
European Medicines Agency 
(EMEA) 
http://www.emea.eu.int/ 
Food and Drug Administration 
(FDA) 
http://www.fda.gov 
Regulation Units 
Medicines and Healthcare 
products Regulatory Agency 
http://www.mhra.gov.uk/ 
PharmaLive http://www.pharmabusiness.com 
Pharmaceutical Research and 
Manufacturers of America  
http://www.phrma.org 
PJB Pharmaprojects Online http://www.pjbpubs.com/pharmaprojects/web.htm 
Information on new 
drugs 
Pharma Times http://www.pharmatimes.com 
Medical Device Daily http://www.medicaldevicedaily.com 
Association of European 
Medical Technology Industry  
http://www.eucomed.be 
Information on new 
medical devices 
Association of American 
Medical Technology Industry 
http://www.advamed.com 
Information on new 
digital health 
technologies  
Future Health Bulletin http://www.headstar.com/futurehealth/ 
Science Daily Magazine http://www.sciencedaily.com 
British Medical Journal http://www.bmj.com 
Journal of American Medical 
Association 
http://www.jama.ama-assn.org 
The Lancet http://www.thelancet.com/journals 
Nature Medicine http://www.nature.com/nm/ 
Information on 
Developments in 
Science 
Science Magazine http://www.sciencemag.org/ 
Reuters Health http://www.reutershealth.com 
Ivanhoe Medical Breakthrough http://www.ivanhoe.com/ 
CNN.com Health http://www.cnn.com/health 
Newswires related 
to Healthcare 
New York Times online, health 
section 
http://www.nytimes.com/pages/health/index.htm 
Doctor’s Guide http://www.docguide.com 
Medscape http://www.Medscape.com 
EurekAlert http://www.eurekalert.org 
National Electronic Library for 
Health 
http://www.nelh.nhs.uk 
Informa Healthcare http://www.pjbpubs.com/ 
Health portals 
NetDoktor http://www.netdoktor.com 
 
 
